500 related articles for article (PubMed ID: 31449975)
1. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
2. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname MH; Rocha VZ; Santos RD
Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
[TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
4. Lipid-Lowering Agents.
Hegele RA; Tsimikas S
Circ Res; 2019 Feb; 124(3):386-404. PubMed ID: 30702996
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
6. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.
Chan DC; Watts GF
Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569
[TBL] [Abstract][Full Text] [Related]
7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
8. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
Larsen LE; Stoekenbroek RM; Kastelein JJP; Holleboom AG
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):349-359. PubMed ID: 30676072
[TBL] [Abstract][Full Text] [Related]
9. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
Kim K; Ginsberg HN; Choi SH
Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
[TBL] [Abstract][Full Text] [Related]
10. The Role of Antisense Therapies Targeting Lipoprotein(a).
Plakogiannis R; Sorbera M; Fischetti B; Chen M
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
[TBL] [Abstract][Full Text] [Related]
11. New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.
Gaine SP; Quispe R; Patel J; Michos ED
Curr Cardiovasc Risk Rep; 2022 Sep; 16(9):69-78. PubMed ID: 36213094
[TBL] [Abstract][Full Text] [Related]
12. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
13. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212
[TBL] [Abstract][Full Text] [Related]
14. Traditional and novel non-statin lipid-lowering drugs.
Jain P
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S38-S43. PubMed ID: 37979722
[TBL] [Abstract][Full Text] [Related]
15. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
[TBL] [Abstract][Full Text] [Related]
16. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
17. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
Stefanutti C; Morozzi C; Di Giacomo S
Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
[TBL] [Abstract][Full Text] [Related]
18. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
19. New Trends in Dyslipidemia Treatment.
Jang AY; Lim S; Jo SH; Han SH; Koh KK
Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
[TBL] [Abstract][Full Text] [Related]
20. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
Sahebkar A; Watts GF
Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
